An interview with Murtada Sesay, country project director in Sierra Leone. SIAPS is working on a two-year project funded by USAID to help rebuild and strengthen the country’s pharmaceutical system following the Ebola epidemic. What’s SIAPS doing in Sierra Leone? Our systems strengthening project there was a consequence, not only of the more recent Ebola, […]
Archive | BlogRSS feed for this section
By Francis (Kofi) Aboagye-Nyame, SIAPS Director You can’t put a price tag on health, but we do have budgets that determine what we can spend to help countries improve theirs. At SIAPS, that means we need to look closely at the impact each dollar we spend has on achieving our goal: strengthening the management of […]
SIAPS supports its country partners by increasing access to effective pharmaceutical products and services and by strengthening pharmaceutical governance. Eliminating stock-outs, avoiding delays, and building human resources and institutional capacity are key to defeating malaria. Below are highlights of some key projects. Building Pharmaceutical Management Capacity in South Sudan Malaria is one of the leading […]
An interview with Andwele Mwansasu, MD, SIAPS Senior Technical Advisor What innovations in fighting malaria over the past five years have particular promise? Has there been a watershed moment? With decreasing malaria burden all over the world, a lot has been happening in the malaria world to sustain these gains. Countries are able to detect […]
Institutionalizing Robust Quantification Processes and Tools within Guinea’s National Malaria Control Program
By Claude Bahati, Deputy Country Project Director, SIAPS, Guinea Accurate quantification for malaria programs, which involves forecasting the quantities needed and planning for the procurement of appropriate pharmaceuticals and supplies, is essential to ensuring that patients receive a continuous supply of commodities. The US Agency for International Development (USAID)-funded Systems for Improved Access to Pharmaceuticals […]
New medicines and regimens, such as bedaquiline, delamanid, and the newly approved short course regimen, are an exciting development given that first- and second-line TB medicines have limited efficacy and potentially serious adverse effects. With the introduction of new TB medicines and regimens, some countries may target only the minimum WHO-recommended conditions (i.e., proper patient […]
TB patients on second-line treatment experience a significant number of adverse effects. Some TB medicines result in adverse effects that, if not continuously monitored, can become serious and/or permanent and may hinder patient adherence to treatment. A number of other risk factors can also impact the safety of patients taking TB medicines, including drug interactions […]
Click on graphic to open larger version.
Bedaqualine (BDQ) is the first new class of antibiotic to come along in decades. Here’s how it’s being introduced to treat drug-resistant TB in many low- and middle-income countries. Scroll over the photos and click for more information.
SIAPS helps high-burden TB countries build their capacity, consensus, and technical skills to strengthen pharmaceutical systems and services. The end goals: Better access to essential medicines, better health outcomes—and a world without TB. Below are highlights of some key projects. The Groundbreaker: Rolling Out a New TB Drug Bedaquiline is the first new class of […]